Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

Occult hepatitis C virus (HCV) infection (OCI) is characterized by the detection of HCV-RNA in non-serum reservoirs, such as peripheral blood mononuclear cells (PBMCs) and/or hepatocytes with undetectable HCV-RNA or antibodies in the serum. In this study, we tried to evaluate the prevalence and poss...

Full description

Saved in:
Bibliographic Details
Published in:Infection and drug resistance Vol. 12; pp. 273 - 279
Main Authors: Mekky, Mohamed A, Sayed, Hani I, Abdelmalek, Mohamed O, Saleh, Medhat A, Osman, Osman A, Osman, Heba A, Morsy, Khairy H, Hetta, Helal F
Format: Journal Article
Language:English
Published: New Zealand Dove Medical Press Limited 01-01-2019
Taylor & Francis Ltd
Dove Medical Press
Subjects:
Alanine
Alanine transaminase
Albumin
Analysis
Antibodies
Antiviral agents
Antiviral drugs
Bilirubin
Biological products industry
Blood
Blood & organ donations
Care and treatment
DAA
Development and progression
Fibrosis
Gastroenterology
HCV
Health aspects
Hepatitis
Hepatitis C
Hepatitis C virus
Hepatocytes
Hepatology
Hospitals
Infection
Infections
Interferon
Laboratories
Leukocytes (mononuclear)
Liver
Medical examination
Medicine
Occult
Original Research
Peripheral blood mononuclear cells
Prothrombin
Ribavirin
Ribonucleic acid
Risk factors
RNA
Sofosbuvir
Software
SVR
Thrombin
Transplants & implants
Viral antibodies
Egypt
United States > US
Direct acting
hepatitis C
Occult
Sofosbuvir
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Occult hepatitis C virus (HCV) infection (OCI) is characterized by the detection of HCV-RNA in non-serum reservoirs, such as peripheral blood mononuclear cells (PBMCs) and/or hepatocytes with undetectable HCV-RNA or antibodies in the serum. In this study, we tried to evaluate the prevalence and possible predictors of OCI in patients who achieved sustained virologic response (SVR) post sofosbuvir/daclatasvir (SOF/DCV) therapy. A cross-sectional multicenter study was designed to enroll 1,280 HCV-infected patients who received SOF (400 mg) plus DCV (60 mg) once daily ± ribavirin regimen for 12 weeks and achieved SVR 12 weeks post treatment. They were randomly recruited from three dedicated Egyptian centers for management of HCV. Real-time PCR was performed to detect HCV-RNA in serum and PBMCs and to evaluate the different risk factors pertaining to the existence of OCI. HCV-RNA was detected in PBMCs of 50 (3.9%) of them. All OCI cases exhibited significant fibrosis score and raised pre-treatment alanine aminotransferase (ALT) levels. Logistic regression analysis comparing OCI with non-OCI revealed that high pre-treatment viral load, raised ALT, advanced fibrosis score, prolonged prothrombin time, low albumin, Child B score, antiviral experienced patients, and raised bilirubin are the most significant predictor for the possibility of OCI presence with Odds Ratio as 7.03, 5.13, 4.4, 2.68, 2.52, 1.9, 1.5, and 1.2, respectively. In spite of its remote possibility, OCI post SOF/DCV therapy may be present in some cases, and this may entail a re-auditing for the definition of SVR by dual testing in both serum and PBMCs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1178-6973
1178-6973
DOI:10.2147/IDR.S181638